These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31572370)

  • 1. Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action.
    Buckley PR; Alden K; Coccia M; Chalon A; Collignon C; Temmerman ST; Didierlaurent AM; van der Most R; Timmis J; Andersen CA; Coles MC
    Front Immunol; 2019; 10():2150. PubMed ID: 31572370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
    Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
    Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
    Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
    Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
    Garçon N; Chomez P; Van Mechelen M
    Expert Rev Vaccines; 2007 Oct; 6(5):723-39. PubMed ID: 17931153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
    Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
    Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
    Fochesato M; Dendouga N; Boxus M
    Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
    Alving CR; Rao M; Matyas GR
    Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
    Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
    BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses.
    Qiao M; Murata K; Davis AR; Jeong SH; Liang TJ
    Hepatology; 2003 Jan; 37(1):52-9. PubMed ID: 12500188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.
    Neeland MR; Shi W; Collignon C; Meeusen ENT; Didierlaurent AM; de Veer MJ
    Clin Exp Immunol; 2018 Apr; 192(1):46-53. PubMed ID: 29194575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
    Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
    J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.